𝗪𝗶𝗹𝗹 𝗥𝗲𝗯𝗹𝗼𝘇𝘆𝗹 𝗖𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝘁𝗼 𝗦𝗲𝗲 𝘁𝗵𝗲 𝗧𝗵𝗶𝗻𝗻𝗲𝘀𝘁 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗜𝗻𝘁𝗲𝗻𝘀𝗶𝘁𝘆?
August 27, 2026: New Biosimilar Spotlight
𝗧𝗵𝗲 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆:
Luspatercept (Reblozyl), a $2.3B market with $4B peak sales, has stayed out of almost every biosimilar pipeline
💉 Indicated for anemia in Beta Thalassemia & Myelodysplastic Syndromes (MDS), both rare & low-prevalence indications
📅 Approved by FDA in 2019 & EMA in 2020; Carries Orphan Drug designation
📈 Extraordinary topline growth: $1B in 2023 → $2.3B in 2025, powered by the 2023 FDA first-line approval for ESA-naive MDS patients, which expanded the addressable market
🤝 Co-developed by Acceleron & Celgene. Celgene was acquired by Bristol Myers Squibb in 2019 and Acceleron acquired by Merck in 2021, giving both companies stakes in Reblozyl’s future
𝗧𝗵𝗲 𝗗𝘂𝗮𝗹 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿 𝗗𝗲𝗳𝗲𝗻𝘀𝗲:
Reblozyl is commercialized by BMS with Merck receiving tiered royalties on sales
⚠️ Two major innovators with direct economic incentive to defend exclusivity aggressively is an unusual dynamic rarely seen in biosimilar targets and one that makes patent litigation even more formidable
𝗧𝗵𝗲 𝗧𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹 𝗕𝗮𝗿𝗿𝗶𝗲𝗿:
Luspatercept is a recombinant Fc-fusion protein & structurally harder to reverse-engineer and prove similarity than standard mAbs
⚠️ Glycosylation sensitivity & structural characterization complexity raise the technical bar and CMC costs significantly
🔬 The only Fc-fusion precedents in advanced markets are Etanercept (Enbrel) & Aflibercept (Eylea), both pursued because their unusually high market sizes compelled developers to absorb the complexity.
Luspatercept’s specific structure and opportunity size (an ActRIIB ligand trap) has no biosimilar precedent, making this a genuinely uncharted technical challenge
𝗧𝗵𝗲 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗶𝘀 𝗔𝗹𝗺𝗼𝘀𝘁 𝗩𝗮𝗰𝗮𝗻𝘁:
🔍 Sandoz is the only player to have disclosed Luspatercept in its biosimilar pipeline
📅 Earliest US LoE: 2033 and Orphan_Drug exclusivity to potentially add further friction before actual market entry
𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗦𝗵𝗼𝘂𝗹𝗱 𝗯𝗲 𝗼𝗻 𝗬𝗼𝘂𝗿 𝗥𝗮𝗱𝗮𝗿:
Biosimilar players still have time to include Luspatercept in their mix:
✅ For scientifically superior developers with Fc-fusion protein expertise, the competitive landscape can be attractive even at $4B ticket size
❌ For players chasing megablockbuster targets in established immunology/oncology indications, this may not make the cut
𝗧𝗵𝗲 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗗𝗲𝗮𝗱𝗹𝗶𝗻𝗲:
By 2028 we should know if Luspatercept gets added to more portfolios or if this quietly goes the Natalizumab way – What’s your view?
Market Report by: Ashwinder Singh Chowdhary
Website: https://www.ounsh.com/
Linkedin: https://www.linkedin.com/company/ounsh/
